Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to $403027.0.

  • Dare Bioscience's Share-based Compensation fell 2302.45% to $403027.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 3021.38%. This contributed to the annual value of $2.2 million for FY2024, which is 1293.83% down from last year.
  • According to the latest figures from Q3 2025, Dare Bioscience's Share-based Compensation is $403027.0, which was down 2302.45% from $359018.0 recorded in Q2 2025.
  • Dare Bioscience's 5-year Share-based Compensation high stood at $650186.0 for Q2 2023, and its period low was $359018.0 during Q2 2025.
  • In the last 5 years, Dare Bioscience's Share-based Compensation had a median value of $532133.0 in 2022 and averaged $506923.4.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 12749.86% in 2021, then crashed by 3988.26% in 2025.
  • Quarter analysis of 5 years shows Dare Bioscience's Share-based Compensation stood at $388806.0 in 2021, then surged by 36.86% to $532133.0 in 2022, then grew by 16.47% to $619791.0 in 2023, then decreased by 21.06% to $489260.0 in 2024, then decreased by 17.63% to $403027.0 in 2025.
  • Its Share-based Compensation stands at $403027.0 for Q3 2025, versus $359018.0 for Q2 2025 and $377357.0 for Q1 2025.